| Code | 9826A | ||||||||||
| MA number | 42/0150/14-S | ||||||||||
| Product Form: | sol inf 25x250 ml/400 mg (vak polyolefínový) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Decentralised | ||||||||||
| MAH, country: | Fresenius Kabi s.r.o., Czechia | ||||||||||
| Therapeutic Class: | 42 - CHEMOTHERAPEUTICA (VRATANE TUBERKULOSTATIK) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Route of admin.: | Intravenous use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 29.04.2014 |
| Pediatric contraindication: | Yes |
| PIL: |
PIL_Moxifloxacin Kabi 400 mg_250 ml sol inf-fľaša_06.2024.pdf
|
| PIL: |
PIL_Moxifloxacin Kabi 400 mg_250 ml sol inf-vak_06.2024.pdf
|
| SPC: |
SPC_Moxifloxacin Kabi 400 mg_250 ml sol inf_06.2024.pdf
|
| Safety feature | Yes |
| Data update: | 09.09.2019 |
